

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 618 189 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 94200746.9

(51) Int. Cl.⁵: **C07C 233/54, C07C 237/46, A61K 49/04**

(22) Date of filing: 23.03.94

(30) Priority: 29.03.93 US 38371

(43) Date of publication of application:
05.10.94 Bulletin 94/40

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**


(71) Applicant: **STERLING WINTHROP INC.**
90 Park Avenue
New York, NY 10016 (US)

(72) Inventor: **Bacon, Edward R., c/o Sterling
Winthrop Inc.**
90 Park Avenue
New York, New York 10016 (US)

(74) Representative: **Haile, Helen Cynthia et al**
Kodak Limited
Patent Department
Headstone Drive
Harrow, Middlesex HA1 4TY (GB)

(54) **Iodinated aromatic propanedioates and their use as X-ray contrast agents.**

(57) Compounds having the structure



wherein (Z)COO is the residue of an iodinated aromatic acid;

R¹ and R² are independently alkyl, fluoroalkyl, cycloalkyl, aryl or aralkyl; and

R³ is H, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy, cyano, sulfonate, carboxamido, sulfonamido, CO₂-alkyl, CO₂-aryl or CO₂-aralkyl;

are useful as contrast agents in x-ray imaging compositions and methods for diagnostic imaging.


EP 0 618 189 A1

This invention relates to iodinated aromatic propanedioates which are particularly useful as contrast agents for x-ray imaging.

X-ray imaging is a well known and extremely valuable tool for the early detection and diagnosis of various disease states in the human body. The use of contrast agents for image enhancement in medical x-ray imaging procedures is widespread. An excellent background on iodinated and other contrast agents for medical imaging is provided by D.P. Swanson *et al*, Pharmaceuticals in Medical Imaging, 1990, MacMillan Publishing Company.


The following references describe various iodine containing compounds useful in preparing x-ray contrast compositions.

U.S. Patent 3,097,228 describes derivatives of 2,4,6-triodobenzoyloxyalkanoic acids having the structure



wherein R¹ is H or lower alkyl; R² is H or lower-alkanoyl; and R³ is H or lower alkanoylamino and R⁴ is lower alkyl.

U.S. Patent 3,144,479 describes iodinated benzoic acid esters having the formula



wherein X is an iodine atom or an amino group and R is selected from H, alkyl, alkoxyalkyl, i.e. (CH₂)_m-O-R'', wherein R'' is alkyl and m is 1 or 2, phenyl and a particular iodinated aromatic group.


However, these references do not disclose or suggest compounds featuring an ester group linked to an alkanate group on an iodinated aromatic ring.

Published European specification EP-A-0 498,482 describes nanoparticulate x-ray contrast compositions which have proven to be extremely useful in medical imaging. However, particulate contrast agents in certain *in vivo* applications can exhibit less than fully satisfactory solubility profiles and/or enzymatic degradation, e.g. in plasma and blood.

It would be desirable to provide compounds for use as x-ray contrast agents having improved enzymatic degradability and appropriate solubility profiles.

Novel iodinated aromatic propanedioates have now been discovered and prepared which are useful as contrast agents in x-ray imaging compositions and methods.

More specifically, in accordance with this invention, there are provided compounds having the structure



wherein (Z)COO is the residue of an iodinated aromatic acid;

R¹ and R² are independently alkyl, fluoroalkyl, cycloalkyl, aryl or aralkyl;

R³ is H, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy, cyano, sulfonate, carboxamido, sulfonamido, CO₂-alkyl, CO₂-aryl or CO₂-aralkyl.

This invention further provides an x-ray contrast composition comprising the above-described compound and a method for medical x-ray diagnostic imaging which comprises administering to the body of a test subject an effective contrast producing amount of the above-described x-ray contrast composition.

It is an advantageous feature of this invention that novel compounds are provided which find particular utility as x-ray contrast agents.

It is another advantageous feature of this invention that compounds are provided having improved enzymatic degradability and appropriate solubility profiles.

In structural formula I above, (Z)COO is the residue of an iodinated aromatic acid. The iodinated acid can comprise one, two, three or more iodine atoms per molecule. Preferred species contain at least two, and more preferably, at least three iodine atoms per molecule. The iodinated compounds can contain substituents which do not deleteriously effect the contrast enhancing capability of the compound.

Illustrative examples of suitable aromatic acids include

diatrizoic acid,
metrizoic acid,
urokonic acid,
iothalamic acid,
trimesic acid,
ioxaglic acid (hexabrix),
ioxitalamic acid,
tetraiodoterephthalic acid,
iodipamide, and the like.


In preferred embodiments, (Z)COO is the residue of a substituted triiodobenzoic acid such as an acyl, carbamyl, and/or acylamino substituted triiodobenzoic acid.

R¹ and R² independently represent linear or branched alkyl, preferably containing from 1 to 20, more preferably 1 to 8 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and the like; fluoroalkyl, the alkyl portion of which is as described above and containing from 1 to (2m + 1) fluorine atoms (where m = the number of carbon atoms in the alkyl group) such as trifluoromethyl; cycloalkyl, preferably containing from 3 to 8 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; aryl, preferably containing from 6 to 10 carbon atoms, such as phenyl and naphthyl; or aralkyl, preferably containing from 7 to 12 carbon atoms, such as benzyl; or halogen, such as chlorine.

R³ represents H; alkyl as defined above; fluoroalkyl, the alkyl portion of which is as described above and containing from 1 to (2m + 1) fluorine atoms (where m = the number of carbon atoms in the alkyl group) such as trifluoromethyl; cycloalkyl as defined above; aryl as defined above; aralkyl as defined above; alkoxy, the alkyl portion of which contains from 1 to 20 carbon atoms as described above; aryloxy, the aryl portion of which preferably contains from 6 to 10 carbon atoms as described above; cyano; sulfonate; carboxamido; sulfonamido; CO₂-alkyl, the alkyl portion of which is as defined above; CO₂-aryl, the aryl portion of which is as defined above; CO₂-aralkyl, the aralkyl portion of which is as defined above, and the like.


The alkyl, cycloalkyl, aryl, aralkyl and alkoxy groups in formula I above can be unsubstituted or substituted with various substituents which do not adversely affect the stability or efficacy of the compounds as x-ray contrast agents such as alkyl, cycloalkyl, aryl, aralkyl, alkoxy, hydroxy, acyloxy, halogen, such as fluorine, chlorine, bromine and iodine, acylamino, carboalkoxy, carbamyl and the like. However, reactive substituents such as halogen are not preferred on the carbon atoms, if present on activated positions in the molecule.

The compounds of this invention can be prepared by contacting the carboxylate of an iodinated aromatic acid with a functionalized propanedioate having the formula



wherein X is a leaving group and R¹-R³ are as defined above, in a suitable solvent. Suitable leaving groups include halogen, such as bromine, iodine and chlorine, and sulfonyloxy, such as methanesulfonyloxy and toluenesulfonyloxy. The carboxylates of iodinated aromatic acids and functionalized propanedioates useful as the starting materials in the preparation of the compounds of this invention are known compounds and/or can be prepared by techniques known in the art. For example, suitable propanedioates include commercially available bromopropanedioate derivatives as exemplified below.

A general reaction scheme is as follows:







The reaction can take place at various temperatures ranging between -78 °C and 100 °C, and preferably -40 °C and 50 °C. For convenience, the reaction can take place at ambient pressure, however, higher and lower pressures are contemplated.

The reaction can take place in any suitable solvent. Suitable solvents include N,N-dimethylformamide (DMF).

The following are specific illustrative examples of preferred compounds of this invention that have been prepared:

- (1) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate,
- (2) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate,
- (3) 1,3-Bis(2-propoxy)-1,3-bis(oxo)-2-propyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate,
- (4) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-5-acetyl(methyl)amino-2,4,6-triiodobenzoate,
- (5) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3-acetylamino-5-N-methylacetylamino-2,4,6-triiodobenzoate,
- (6) 1,3-Bis(2-propoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-5-N-methylacetylamino-2,4,6-triiodobenzoate,
- (7) Bis-[(1,3-bis(ethoxy)-1,3-bis(oxo)-2-propyl 2,4,6-triiodo-5-acetylaminoisophthalate,
- (8) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-2,4,6-triiodobenzoate, and
- (9) 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3-acetylamino-2,4,6-triiodobenzoate.

Preferred compounds of this invention conform to formula I above, as indicated below:

Compound	Z	R ¹	R ²	R ³
1		C ₂ H ₅	C ₂ H ₅	H
2	..	C ₂ H ₅	C ₂ H ₅	CH ₃
3	..	i-C ₃ H ₇	i-C ₃ H ₇	H
4		C ₂ H ₅	C ₂ H ₅	H
5	..	C ₂ H ₅	C ₂ H ₅	CH ₃
6	..	i-C ₃ H ₇	i-C ₃ H ₇	H
7		C ₂ H ₅	C ₂ H ₅	H
8		C ₂ H ₅	C ₂ H ₅	H
9	..	C ₂ H ₅	C ₂ H ₅	CH ₃

When used as an x-ray contrast agent, the compound of this invention preferably comprises at least about 35%, more preferably 40% iodine by weight.

In preferred embodiments, the compounds of this invention can be formulated into particulate x-ray contrast compositions, preferably nanoparticulate x-ray contrast compositions, as described in commonly-owned published European specification EP-A-O 498,482. Such nanoparticulate compositions can be prepared by dispersing the compounds of the invention in a liquid dispersion medium, and wet grinding the compound in the presence of rigid grinding media and a surface modifier to form the nanoparticles. Alternatively, the surface modifier can be contacted with the compound after attrition.

The x-ray contrast compositions of this invention comprise the above-described compounds, preferably in the form of particles, and a physiologically acceptable carrier therefor. For example, the particles can be dispersed in an aqueous liquid which serves as the carrier for the x-ray contrast agent. Other suitable carriers include liquid carriers such as mixed aqueous and nonaqueous solvents, such as alcohol; gels;

gases, such as air; and powders.

The x-ray contrast composition can comprise from about 1-99.9 %, preferably 2-45 % and more preferably 10-25% by weight of the above-described particles, the remainder of the composition being the carrier, additives and the like. Compositions up to about 100% by weight of the particles are contemplated when the composition is in a lyophilized form.

The dose of the contrast agent to be administered can be selected according to techniques known to those skilled in the art such that a sufficient contrast enhancing effect is obtained. Typical doses can range from 50 to 350 mg iodine/kg body weight of the subject for many imaging applications. For some applications, e.g. lymphography, lower doses, e.g. 0.5-20 mg I/kg, can be effective.

The x-ray contrast composition can contain one or more conventional additives used to control and/or enhance the properties of the x-ray contrast agent. For example, thickening agents such as dextran or human serum albumin, buffers, viscosity regulating agents, suspending agents, peptizing agents, anti-clotting agents, mixing agents, and other drugs and the like can be added. A partial listing of certain specific additives includes gums, sugars such as dextran, human serum albumin, gelatin, sodium alginate, agar, dextrin, pectin and sodium carboxymethyl cellulose. Such additives, surface active agents, preservatives and the like can be incorporated into the compositions of the invention.

A method for diagnostic imaging for use in medical procedures in accordance with this invention comprises administering to the body of a test subject in need of an x-ray an effective contrast producing amount of the above-described x-ray contrast composition. In addition to human patients, the test subject can include mammalian species such as rabbits, dogs, cats, monkeys, sheep, pigs, horses, bovine animals and the like. Thereafter, at least a portion of the body containing the administered contrast agent is exposed to x-rays to produce an x-ray image pattern corresponding to the presence of the contrast agent. The image pattern can then be visualized. For example, any x-ray visualization technique, preferably, a high contrast technique such as computed tomography, can be applied in a convention manner. Alternatively, the image pattern can be observed directly on an x-ray sensitive phosphor screen-silver halide photographic film combination.

The compositions of this invention can be administered by a variety of routes depending on the type of procedure and the anatomical orientation of the tissue being examined. Suitable administration routes include intravascular (arterial or venous) administration by catheter, intravenous injection, rectal administration, subcutaneous administration, intramuscular administration, intralesional administration, intrathecal administration, intracisternal administration, oral administration, administration via inhalation, administration directly into a body cavity, e.g. arthrography, and the like.

In addition to preferred applications, i.e. for blood pool, liver, spleen and lymph node imaging, the x-ray contrast compositions of this invention are also expected to be useful as contrast agents for any organ or body cavity. For example, the compositions of this invention are expected to be useful as angiographic contrast media, urographic contrast media, myelographic contrast media, gastrointestinal contrast media, cholecystographic and cholangiographic contrast media, arthrographic contrast media, hysterosalpingographic contrast media, oral contrast media and bronchographic contrast media.

The invention will now be illustrated with reference to the following examples but is in no way to be construed as limited thereto.

Example 1 Preparation of 1,3-Bis(ethoxy)-1,3-bis(oxo)-

Compound 1. 2-propyl 3,5-bis-(acetylamino)-2,4,6-triiodobenzoate

To a solution of the sodium salt of diatrizoic acid (sodium hypaque) (98.8g, 155.3 mmoles) in dry DMF (600 ml) was added, in several portions, a solution of diethyl 2-bromomalonate in 50 ml DMF, and the reaction mixture was stirred for 12 hrs at ambient temperature. The solution was then added dropwise, rapidly, to 5 l ice water and the resulting white precipitate was collected, washed with water followed by ether. The solid was dried at 110 °c under vacuum to give 110.6g (92%) of analytically pure product, mp 258-265 °C (dec. 279 °C); CI-MS: MH+ 773.

The ¹H-NMR (300 MHz) spectral data was consistent with the desired material.

Calculated for C₁₈H₁₉I₃N₂O₈:

	C 28.00,	H 2.48,	I 49.31,	N 3.63,
Found:	C 27.80,	H 2.25,	I 49.55,	N 3.53.

Exempl 2 Preparation of 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3,5-bis(acetylamino)-2,4,6-triodobenzoateCompound 2.

5 A solution of sodium hypaque (50g, 79 mmole) in 150 ml dry DMF was treated with 16.6 ml (87 mmole) of diethyl 2-bromo-2-methylmalonate and the reaction mixture was heated for 12 hrs on a steam bath. After cooling, the solution was added to ice water and the resulting precipitate was collected by filtration, rinsed with water, ethyl acetate and dried under vacuum. The product was recrystallized from DMF-water to give
 10 48.4g (69%) of pure material, mp 268-269 °C (dec.); CI-MS: MH⁺ 787. The ¹H-NMR (300 MHz) spectral data was consistent with the desired material.

Calculated for C ₁₉ H ₂₁ I ₃ N ₂ O ₈ :				
	C 29.03,	H 2.69,	N 3.56,	I 48.43;
Found:	C 28.82,	H 2.56,	N 3.57,	I 48.83.

Example 3 Preparation of 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-5-acetyl(methyl)amino-2,4,6-triodobenzoateCompound 4.

25 To a solution of the sodium salt of metrizoic acid (68.7g, 92 mmole) in 175 ml dry DMF was added 17.3 ml (100 mmole) of diethyl 2-bromomalonate and the mixture was stirred for 72 hrs at ambient temperature. The solution was then poured into 2.5 l water and the crude white product was collected and washed with ether and dried at 110 °C under vacuum to give 72.8g (99%) of analytically pure solid, mp 200 - 203 °C; CI-MS: MH⁺ 787. The ¹H-NMR (300 MHz) spectral data was consistent with the proposed structure.


Calculated for C ₁₉ H ₂₁ I ₃ N ₂ O ₈ :				
	C 29.03,	H 2.69,	N 3.56,	I 48.43,;
Found:	C 28.88,	H 2.47,	N 3.50,	I 48.11.

Examples 4-9

40 In a manner similar to the procedures described in Examples 1 - 3 above, the other compounds set forth in the Table above were prepared. In each case, the MS and spectral data (300 MHz) were consistent with the desired product.

Claims

- 45 1. A compound having the structure



55 wherein (Z)COO is the residue of an iodinated aromatic acid;

R¹ and R² are independently alkyl, fluoroalkyl, cycloalkyl, aryl, or aralkyl; and

R³ is H, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy, cyano, sulfonate, carboxamido, sulfonamido, CO₂-alkyl, CO₂-aryl, or CO₂-aralkyl.

2. A compound as claimed in claim 1 wherein (Z)COO is the residue of an iodinated aromatic acid selected from:
diatrizoic acid,
metrizoic acid,
5 urokonic acid,
iothalamic acid,
trimesic acid,
ioxagalic acid,
ioxitalamic acid,
10 tetraiodoterephthalic acid and
iodipamide.
3. A compound as claimed in claim 1 wherein (Z)COO is the residue of diatrizoic acid.
- 15 4. A compound as claimed in claim 1 wherein R¹ and R² are ethyl or propyl.
5. A compound as claimed in claim 1 wherein R³ is H or methyl.
6. A compound as claimed in claim 1 wherein said compound is selected from the group consisting of
20 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate, 1,3-Bis(ethoxy)-1,3-bis-
(oxo)-2-methylpropyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate, 1,3-Bis(2-propoxy)-1,3-bis(oxo)-2-propyl
3,5-bis(acetylamino)-2,4,6-triiodobenzoate, 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-5-acetyl-
(methyl)amino-2,4,6-triiodobenzoate, 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3-acetylamino-5-N-
25 methylacetylamino-2,4,6-triiodobenzoate, 1,3-Bis(2-propoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-5-N-
methylacetylamino-2,4,6-triiodobenzoate, Bis-[(1,3-bis(ethoxy)-1,3-bis(oxo)-2-propyl 2,4,6-triiodo-5-ac-
etylaminoisophthalate, 1,3-Bis(ethoxy)-1,3-bis(oxo)-2-propyl 3-acetylamino-2,4,6-triiodobenzoate, and
1,3-Bis(ethoxy)-1,3-bis(oxo)-2-methylpropyl 3-acetylamino-2,4,6-triiodobenzoate.
7. An x-ray contrast composition comprising a compound as claimed in any one of the preceding claims.
- 30 8. An x-ray contrast composition as claimed in claim 7 further including a pharmaceutically acceptable carrier.
9. A method for medical x-ray diagnostic imaging which comprises administering to the body of a
35 mammal a contrast effective amount of an x-ray contrast composition as claimed in either of claims
claim 7 and 8.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 94 20 0746
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.5)
D,A	US-A-3 097 228 (A.A. LARSEN) * claims; examples * ---	1-8	C07C233/54 C07C237/46 A61K49/04
A	M. VERDERAME 'CRC Handbook of Hormones, Vitamins, and Radiopaques', CRC PRESS, BACO RATON, FLORIDA US * page 229 - page 243 * -----	1-8	
			TECHNICAL FIELDS SEARCHED (Int.Cl.5)
			C07C A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		16 June 1994	Pauwels, G
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	



EP 94 20 0746

-C-

INCOMPLETE SEARCH

Claims searched completely: 1-8

Claim not searched: 9

Method for treatment of the human or
animal body by surgery or therapy
(see article 52(4) of the European
Patent Convention)